FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a method for treating primary Sjögren's syndrome in a human, which includes administering a therapeutically effective dose of an anti-CD40 antibody to said human.
EFFECT: invention has the ability to effectively treat Sjögren's syndrome in humans.
9 cl, 27 dwg, 5 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| ANTI-HER2 ANTIBODY DRUGS FOR SUBCUTANEOUS INJECTION | 2018 |
|
RU2750821C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
